European manufacturers are complaining that one of their largest export markets — Turkey — has unfairly erected barriers to doing business in the country. The European Union has responded by filing a dispute with the World Trade Organization.

In its complaint, filed on April 2, the EU maintained the Turkish government has taken several steps that are designed to bolster its economy and local producers at the expense of foreign drug makers selling their medicines there. And the moves could potentially affect EU pharmaceutical exports worth approximately $520 million.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that I was happy to see this appear toward the end of this post – “As for technology transfer as a condition of market access, he continued, “we [ also ] saw this in China…” I was made aware of this 15+ years ago and it had been concerning companies well before I became aware.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy